Gamco Investors INC. ET AL lessened its position in shares of Allergan plc (NYSE:AGN) by 3.0% in the fourth quarter, Holdings Channel reports. The fund owned 67,948 shares of the company’s stock after selling 2,075 shares during the quarter. Gamco Investors INC. ET AL’s holdings in Allergan were worth $11,115,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. Edgewood Management LLC increased its position in Allergan by 24.3% during the third quarter. Edgewood Management LLC now owns 4,445,924 shares of the company’s stock valued at $911,192,000 after acquiring an additional 869,248 shares during the last quarter. Baupost Group LLC MA increased its position in Allergan by 21.9% during the third quarter. Baupost Group LLC MA now owns 2,964,203 shares of the company’s stock valued at $607,513,000 after acquiring an additional 531,600 shares during the last quarter. Epoch Investment Partners Inc. increased its position in Allergan by 1.0% during the third quarter. Epoch Investment Partners Inc. now owns 1,805,608 shares of the company’s stock valued at $370,060,000 after acquiring an additional 17,068 shares during the last quarter. Legal & General Group Plc increased its position in Allergan by 5.3% during the third quarter. Legal & General Group Plc now owns 1,739,410 shares of the company’s stock valued at $356,484,000 after acquiring an additional 87,953 shares during the last quarter. Finally, Iridian Asset Management LLC CT increased its position in Allergan by 4.8% during the fourth quarter. Iridian Asset Management LLC CT now owns 1,712,404 shares of the company’s stock valued at $280,115,000 after acquiring an additional 78,455 shares during the last quarter. Institutional investors own 80.23% of the company’s stock.

In other Allergan news, Director Chris W. Bodine bought 3,030 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The stock was purchased at an average price of $164.77 per share, for a total transaction of $499,253.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman Brent L. Saunders bought 4,600 shares of the business’s stock in a transaction that occurred on Wednesday, December 6th. The shares were acquired at an average price of $164.74 per share, with a total value of $757,804.00. The disclosure for this purchase can be found here. Insiders have purchased 17,630 shares of company stock valued at $2,890,057 in the last quarter. 0.36% of the stock is currently owned by company insiders.

A number of analysts recently commented on AGN shares. Cantor Fitzgerald set a $191.00 price objective on Allergan and gave the company a “hold” rating in a research report on Tuesday, December 12th. Vetr cut Allergan from a “hold” rating to a “sell” rating and set a $180.97 price objective for the company. in a research report on Monday, January 22nd. Credit Suisse Group set a $243.00 price objective on Allergan and gave the company an “outperform” rating in a research report on Tuesday, October 17th. Citigroup reduced their price objective on Allergan from $280.00 to $240.00 and set a “buy” rating for the company in a research report on Thursday, October 19th. Finally, Bank of America upped their price objective on Allergan from $208.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the stock. Allergan currently has an average rating of “Buy” and a consensus price target of $227.23.

Shares of Allergan plc (AGN) opened at $164.20 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.08 and a current ratio of 2.04. Allergan plc has a 1 year low of $160.07 and a 1 year high of $256.80. The stock has a market capitalization of $56,668.84, a PE ratio of -12.24, a P/E/G ratio of 1.26 and a beta of 1.19.

Allergan (NYSE:AGN) last released its earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.74 by $0.12. Allergan had a positive return on equity of 8.28% and a negative net margin of 26.32%. The firm had revenue of $4.33 billion during the quarter, compared to analysts’ expectations of $4.28 billion. During the same quarter last year, the business posted $3.90 earnings per share. The firm’s revenue was up 12.0% on a year-over-year basis. analysts forecast that Allergan plc will post 15.44 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Gamco Investors INC. ET AL Trims Position in Allergan plc (AGN)” was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/02/09/gamco-investors-inc-et-al-trims-position-in-allergan-plc-agn.html.

Allergan Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.